Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360
android app
/
iOS App/ web portal.
{
"products": [
{
"_id": "69a9837a9c219e2cff873568",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "dapagliflozin glimepiride metformin tablet",
"description": "Composition: Dapagliflozin 10 mg + Glimepiride 2 mg + Metformin Hydrochloride 500 mg (Extended Release)\n\nManaging type 2 diabetes requires a balanced approach that includes proper medication, healthy lifestyle choices, and regular monitoring of blood sugar levels. Modern diabetes management often involves combination therapies that target blood glucose control through multiple mechanisms. One such effective combination medicine is GLIDAPAFLOZIN TRIO 2.\n\nThis medication contains three well-known antidiabetic agents—Dapagliflozin, Glimepiride, and Metformin Hydrochloride in an extended-release formulation. Together, these medicines work in different ways to help control blood sugar levels effectively in adults with type 2 diabetes.\n\nThis article provides a comprehensive overview of the product, its uses, benefits, possible side effects, and important information patients should know before using it.\n\nProduct Overview\n\nGLIDAPAFLOZIN TRIO 2 is a triple-combination oral antidiabetic tablet designed to help manage blood glucose levels in patients diagnosed with Type 2 Diabetes.\n\nEach tablet contains:\n\nDapagliflozin 10 mg\n\nGlimepiride 2 mg\n\nMetformin Hydrochloride 500 mg (Extended Release)\n\nThese ingredients work together to reduce high blood sugar levels through complementary mechanisms, helping patients achieve better glycemic control.\n\nCombination therapy like this is commonly recommended when a single medication alone is not sufficient to manage blood glucose levels.\n\nHow the Medicine Works\n\nThe three active ingredients in GLIDAPAFLOZIN TRIO 2 work through different pathways in the body.\n\n1. Dapagliflozin\n\nDapagliflozin belongs to a class of drugs known as SGLT2 inhibitors. It works by helping the kidneys remove excess glucose from the body through urine. This reduces blood sugar levels and may also provide additional cardiovascular and kidney benefits in some patients.\n\n2. Glimepiride\n\nGlimepiride stimulates the pancreas to release more insulin. Insulin is the hormone responsible for moving glucose from the bloodstream into cells where it can be used as energy.\n\n3. Metformin Hydrochloride (Extended Release)\n\nMetformin Hydrochloride helps lower blood sugar by reducing glucose production in the liver and improving insulin sensitivity in the body. The extended-release formulation ensures a steady release of the medicine over time, improving tolerance and effectiveness.\n\nTogether, these three medicines provide a comprehensive approach to blood sugar management.\n\nUses of GLIDAPAFLOZIN TRIO 2\n\nGLIDAPAFLOZIN TRIO 2 is primarily prescribed for the management of Type 2 Diabetes in adults.\n\nMain Uses\n\nBlood Sugar Control\nThe medication helps reduce high blood glucose levels in patients whose diabetes is not adequately controlled with diet, exercise, or single-drug therapy.\n\nImproving Insulin Function\nIt improves the body’s response to insulin and helps regulate glucose metabolism.\n\nPreventing Diabetes Complications\nProper blood sugar control reduces the risk of long-term complications such as nerve damage, kidney disease, vision problems, and cardiovascular issues.\n\nSupporting Weight and Metabolic Health\nThe presence of dapagliflozin may help some patients experience mild weight reduction and improved metabolic balance.\n\nKey Benefits\n\nThe combination of three effective antidiabetic agents offers several important benefits.\n\n1. Triple Mechanism Action\n\nThe medicine works through three complementary mechanisms, targeting multiple causes of high blood sugar.\n\n2. Better Glycemic Control\n\nPatients often achieve improved HbA1c levels compared to single-drug therapy.\n\n3. Reduced Risk of Long-Term Complications\n\nMaintaining controlled blood sugar levels helps prevent complications associated with diabetes.\n\n4. Convenient Single Tablet Therapy\n\nInstead of taking multiple medicines separately, patients can manage their treatment with a single tablet, improving medication adherence.\n\n5. Extended Release Technology\n\nThe extended-release formulation of Metformin Hydrochloride ensures gradual drug release, reducing stomach discomfort and improving patient tolerance.\n\n6. Improved Energy and Daily Functioning\n\nProper blood sugar control helps patients feel more energetic and maintain better overall health.\n\nPossible Side Effects\n\nLike all medications, GLIDAPAFLOZIN TRIO 2 may cause some side effects. However, not everyone experiences them.\n\nCommon Side Effects\n\nMild stomach discomfort\n\nNausea or vomiting\n\nDiarrhea\n\nHeadache\n\nIncreased urination\n\nLow blood sugar (hypoglycemia), especially when meals are skipped\n\nLess Common Side Effects\n\nUrinary tract infections\n\nDizziness or weakness\n\nMild dehydration\n\nRare but Serious Effects\n\nSevere hypoglycemia\n\nLactic acidosis (very rare but serious condition linked with metformin)\n\nAllergic reactions\n\nPatients should immediately consult a healthcare professional if they experience unusual symptoms such as severe weakness, difficulty breathing, or persistent stomach pain.\n\nPrecautions and Safety Advice\n\nBefore starting GLIDAPAFLOZIN TRIO 2, patients should inform their doctor if they have:\n\nKidney disease\n\nLiver problems\n\nHeart conditions\n\nHistory of severe dehydration\n\nAny known drug allergies\n\nPatients should also avoid skipping meals and maintain proper hydration to reduce the risk of low blood sugar.\n\nRegular monitoring of blood glucose levels is important while using this medication.\n\nLifestyle Tips for Better Results\n\nMedication alone cannot control diabetes. Patients should combine treatment with healthy habits.\n\nRecommended lifestyle practices include:\n\nMaintaining a balanced diabetic diet\n\nExercising regularly\n\nMonitoring blood sugar levels\n\nAvoiding excessive sugar and processed foods\n\nManaging stress levels\n\nGetting sufficient sleep\n\nThese lifestyle changes enhance the effectiveness of diabetes medications.\n\nConclusion\nManaging diabetes requires a consistent and comprehensive approach. Combination medicines like GLIDAPAFLOZIN TRIO 2 provide an effective solution for patients who need stronger glucose control than single-drug therapy can offer.",
"price": 184.0,
"discountamount": 56.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2317,
"imageuri": "https://productimages.withfloats.com/actual/69a9837cad119d5b47141190.png",
"tileimageuri": "https://productimages.withfloats.com/tile/69a9837cad119d5b47141190.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2026-03-05T13:22:02.718Z",
"updatedon": "2026-03-13T11:05:08.762Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/dapagliflozin-glimepiride-metformin-tablet/2317",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLIDAPAFLOZIN TRIO 2",
"category": "DIABETIC RANGE",
"tags": [
"dapagliflozin glimepiride metformin tablet uses and dosage",
"dapagliflozin glimepiride metformin combination tablet benefits",
"dapagliflozin glimepiride metformin tablet side effects in adults",
"dapagliflozin glimepiride metformin tablet how it works",
"dapagliflozin glimepiride metformin tablet benefits for sugar control",
"buy dapagliflozin glimepiride metformin tablet online",
"dapagliflozin glimepiride metformin tablet price in india",
"dapagliflozin glimepiride metformin tablet for uncontrolled diabetes",
"dapagliflozin glimepiride metformin tablet triple therapy medicine",
"dapagliflozin glimepiride metformin tablet dosage guide for adults"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "694e56c05837f90c86a7eb8c",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "empagliflozin linagliptin and metformin",
"description": "LINALIGIP EMPAMET (Empagliflozin, Linagliptin, and Metformin Hydrochloride ER Tablets) stands out as a comprehensive triple therapy for adults with type 2 diabetes mellitus, combining three synergistic agents to tackle hyperglycemia from multiple angles. This once-daily extended-release formulation simplifies adherence while delivering robust glycemic control, weight management, and cardiovascular protection. Patients often seek it for its convenience in managing blood sugar levels when diet, exercise, and single agents fall short.\n\n\nProduct Description and Composition\nLINALIGIP EMPAMET features Empagliflozin (typically 10-25mg), Linagliptin (5 mg), and Metformin Hydrochloride ER (up to 1000mg) in a single tablet, designed for prolonged release to minimize gastrointestinal upset. Empagliflozin, an SGLT2 inhibitor, blocks glucose reabsorption in the kidneys, promoting its excretion via urine. Linagliptin, a DPP-4 inhibitor, enhances incretin hormones like GLP-1 to boost insulin secretion and suppress glucagon. Metformin ER reduces hepatic glucose production and improves insulin sensitivity without hypoglycemia risk.\n\n\nThis unique blend from Steris Healthcare ensures steady drug delivery over 24 hours, reducing peak-trough fluctuations for stable HbA1c reductions of 1.5-2.0%. The extended-release metformin coats the tablet core, dissolving gradually in the intestines for better tolerability compared to immediate-release forms. Ideal for Indian patients facing rising diabetes prevalence, it addresses insulin resistance, postprandial spikes, and caloric overload holistically.\n\n\nMechanism of Action\nThe triple mechanism targets key diabetes pathways: Empagliflozin inhibits SGLT2 in proximal renal tubules, lowering blood glucose by 70-90g daily through glycosuria, independent of insulin. Linagliptin selectively binds DPP-4, prolonging GLP-1 and GIP activity to stimulate glucose-dependent insulin release from beta cells and curb glucagon-mediated gluconeogenesis. Metformin activates AMPK in hepatocytes, inhibiting gluconeogenesis while enhancing peripheral glucose uptake.\n\n\nSynergy amplifies effects—SGLT2 inhibition provides insulin-independent control, DPP-4 boosts prandial responses, and metformin tackles fasting hyperglycemia—resulting in complementary HbA1c drops without overlapping toxicities. Clinical data show this combination yields superior efficacy over dual therapies, with added osmotic diuresis aiding fluid balance.\n\n\nUses and Indications\nLINALIGIP EMPAMET treats type 2 diabetes in adults, as adjunct to diet and exercise, especially when metformin alone or dual therapy inadequately controls glycemia. Primary uses include newly diagnosed patients needing intensification, those with obesity (due to weight loss from glycosuria), and high-risk cardiovascular profiles benefiting from empagliflozin's heart protection. It excels in managing postprandial hyperglycemia, fasting glucose, and preventing complications like nephropathy.\n\n\nPrescribed for patients intolerant to other agents or requiring simplified regimens, it suits Indian demographics with high metabolic syndrome rates. Not for type 1 diabetes or ketoacidosis; renal function (eGFR >45 mL/min) guides initiation.\n\n\nKey Benefits\nLINALIGIP EMPAMET offers multifaceted advantages for long-term diabetes management:\n\nSuperior Glycemic Control: Achieves 1.8% HbA1c reduction in trials, outperforming monotherapies by targeting multiple defects.\n\n\nWeight Loss: Empagliflozin induces 3-5kg loss via caloric excretion, countering metformin's neutral effect.\n\n\nCardiovascular and Renal Protection: Reduces major adverse cardiac events (MACE) by 14% and slows CKD progression, per EMPA-REG outcomes.\n\n\nLow Hypoglycemia Risk: Glucose-dependent actions of linagliptin and empagliflozin minimize lows, unlike sulfonylureas.\n\n\nConvenience: Single-tablet ER dosing improves compliance, vital for busy lifestyles in Jaipur and beyond.\n\n\nBlood Pressure Reduction: Mild diuretic effect lowers systolic BP by 3-5 mmHg.\n\n\nThese benefits enhance quality of life, reducing fatigue, neuropathy risks, and healthcare costs.\n\nSide Effects\nCommon side effects mirror individual components but occur less due to synergy:\n\nGastrointestinal: Metformin ER causes less nausea/diarrhea (10-15%) than IR forms; titrate slowly.\n\n\nGenitourinary: Empagliflozin raises UTI/genital mycotic infection risk (5-10%), managed with hygiene.\n\n\nVolume Depletion: Orthostatic hypotension in 2-3%, especially with diuretics.\n\n\nSerious effects include lactic acidosis (rare, <1/100,000 with metformin in eGFR >30), ketoacidosis (euglycemic, 0.1%), and acute kidney injury. Monitor for dehydration, pancreatitis signs, or bullous pemphigoid with linagliptin. Hypersensitivity rash or bone fractures warrant discontinuation.\n\n\nSide Effect Category\tFrequency\tManagement\nNausea and Diarrhea\tCommon (10%)\tTake with food, slow titration \n\nUTI/Mycotic Infections\tCommon (7%)\tHydration, antifungals \n\nHypoglycemia\tRare (<2%)\tWith insulin, dose adjust \n\nLactic Acidosis\tVery Rare.\tAvoid in renal/hepatic failure \n\nKetoacidosis\tRare (0.1%)\tCheck ketones if nausea \n\nDosage and Administration\nStart with Empagliflozin 10mg/Linagliptin 5mg/Metformin ER 1000mg once daily with morning meal to optimize absorption and reduce GI effects. Titrate metformin to 2000mg max based on tolerance; empagliflozin to 25mg if needed. Swallow whole; no crushing. Adjust for renal impairment (eGFR 30-45: max metformin 1000mg; <30 contraindicated). Elderly start low due to volume sensitivity.\n\n\nMissed dose: Take soon if less than 12 hours late; skip otherwise. Discontinue pre-surgery or contrast use.\n\nPrecautions and Warnings\nAssess eGFR before and 3-6 months after initiation; hold if <45. Caution in dehydration, heart failure, or liver disease risks lactic acidosis. Educate on ketoacidosis symptoms (nausea, fatigue) despite normal glucose. Avoid excessive alcohol; monitor BP in hypertensives. Pregnancy category D—use insulin instead. Breastfeeding is contraindicated.\n\n\nDrug interactions: Adding sulfonylureas/insulin heightens hypoglycemia; rifampin reduces linagliptin levels; ritonavir boosts empagliflozin exposure.\n\nFrequently Asked Questions\nWhat is LINALIGIP EMPAMET used for?\nControls type 2 diabetes via triple action on glucose excretion, incretins, and insulin sensitivity.\n\nDoes it cause weight gain?\nNo—it promotes 2-4 kg loss, unlike some antidiabetics.\n\n\nSafe for kidneys?\nRenal-protective; monitor eGFR.\n\n\nHypoglycemia risk?\nMinimal without sulfonylureas.\n\nConclusion\nLINALIGIP EMPAMET revolutionizes type 2 diabetes care with its potent, convenient triple therapy, delivering glycemic mastery, weight benefits, and cardioprotection unmatched by singles or duos. Backed by landmark trials, it empowers patients toward complication-free lives when integrated with lifestyle changes. Consult physicians for personalized dosing to harness its full potential safely.",
"price": 220.0,
"discountamount": 66.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2257,
"imageuri": "https://productimages.withfloats.com/actual/694e60c1db6d50f75e42e875.png",
"tileimageuri": "https://productimages.withfloats.com/tile/694e60c1db6d50f75e42e875.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-12-26T09:34:56.604Z",
"updatedon": "2026-03-13T10:59:31Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//empagliflozin-linagliptin-and-metformin/2257",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "LINALIGIP EMPAMET",
"category": "DIABETIC RANGE",
"tags": [
"empagliflozin 10 mg",
"empagliflozin 25 mg",
"empagliflozin 10 mg uses in hindi",
"empagliflozin 10 mg tablet.",
"type 2 diabetes mellitus.",
"linagliptin",
"Linagliptin 5 mg",
"linagliptin 5 mg uses",
"linagliptin tablet uses",
"Linagliptin 5 mg price",
"Empagliflozin, an SGLT2 inhibitor.",
"Metformin ER reduces hepatic glucose production and improves insulin.",
"LINALIGIP EMPAMET revolutionizes type 2 diabetes.",
"empagliflozin linagliptin and metformin tablets",
"empagliflozin linagliptin metformin combination tablet",
"empagliflozin linagliptin metformin tablets uses",
"empagliflozin linagliptin metformin triple combination",
"empagliflozin linagliptin metformin dosage strength",
"empagliflozin linagliptin metformin sustained release tablet",
"empagliflozin linagliptin metformin medicine for diabetes",
"empagliflozin linagliptin metformin tablet uses",
"empagliflozin linagliptin metformin benefits",
"empagliflozin linagliptin metformin for type 2 diabetes",
"empagliflozin linagliptin metformin blood sugar control",
"empagliflozin linagliptin metformin weight loss benefit",
"what is empagliflozin linagliptin metformin tablet",
"how does empagliflozin linagliptin metformin work",
"empagliflozin linagliptin metformin tablet price in india",
"empagliflozin linagliptin metformin tablet dosage",
"empagliflozin linagliptin metformin before or after food"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "6662b5587de2b5203089e01d",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "VILDIABATE M 850 ",
"description": "VILDIABATE M 850 \nMetformin (850mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 850\nVILDIABATE M 850 is a combination medication designed to manage type 2 diabetes mellitus effectively. It combines Metformin Hydrochloride Sustained Release (SR) 850mg and Vildagliptin 50mg. This dual-action formulation targets different pathways involved in glucose regulation, providing comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 850mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained-release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 850\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight-neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once or twice daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 850 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-850-133455",
"price": 299.0,
"discountamount": 89.7,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"GIP",
"diet",
"Order",
"EMAIL",
"water",
"glass",
"liver",
"GLP-1",
"peaks",
"meals",
"adults",
"amount",
"option",
"troughs",
"Fasting",
"exercise",
"Low Risk",
"patients",
"readings",
"response",
"Enhancing",
"same time",
"biguanide",
"Guidelines",
"one tablet",
"weight gain",
"Optimal Use",
"information",
"Adjustments",
"utilization",
"Vildagliptin",
"Metformin SR",
"sterispharma",
"Hypoglycemia",
"Introduction",
"best results",
"sterisonline",
"DPP-4 enzyme",
"muscle cells",
"CALL/WHATSAPP",
"treatment plan",
"glucose uptake",
"steady release",
"typical dosage",
"Key Components",
"Administration",
"Weight Neutral",
"Consistent Use",
"low blood sugar",
"Incretin Levels",
"gradual release",
"glycemic control",
"VILDIABATE M 850",
"glucagon release",
"Prolonged Effect",
"DPP-4) inhibitor",
"incretin hormones",
"insulin secretion",
"glucose regulation",
"several mechanisms",
"different pathways",
"Regular monitoring",
"healthcare provider",
"Insulin Sensitivity",
"blood glucose levels",
"Intestinal Absorption",
"combination medication",
"dipeptidyl peptidase-4",
"gastrointestinal tract",
"dual-action formulation",
"meal) blood sugar levels",
"type 2 diabetes mellitus",
"glucose-dependent manner",
"Recommended Dosage Dosage",
"Additional Health Benefits",
"Hepatic Glucose Production",
"Extended Release Formulation",
"sustained-release formulation",
"prolonged therapeutic effects",
"immediate-release formulations",
"Postprandial Glucose Management",
"long-lasting blood sugar control",
"comprehensive blood sugar control",
"sustained-release (SR) formulation",
"common gastrointestinal side effects",
"Reduced Gastrointestinal Side Effects",
"Improving Postprandial Glucose Control",
"glucose-dependent insulinotropic peptide",
"Metformin Hydrochloride Sustained Release"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1504,
"imageuri": "https://productimages.withfloats.com/actual/667d44a2576e8da931df856b.png",
"tileimageuri": "https://productimages.withfloats.com/tile/667d44a2576e8da931df856b.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-07T07:23:04.367Z",
"updatedon": "2026-03-14T06:50:04.324Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//vildiabate-m-850-/1504",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "VILDIABATE M 850 ",
"category": "DIABETIC RANGE",
"tags": [
"vildagliptin metformin 50/850 price",
"vildagliptin and metformin hydrochloride tablets s"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "6662b1e6870e7b20c49e6522",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "VILDIABATE M 500 ",
"description": "VILDIABATE M 500 \nMetformin (500mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 500\nVILDIABATE M 500 is a combination medication designed to manage type 2 diabetes mellitus effectively. It contains Metformin Hydrochloride Sustained Release (SR) 500mg and Vildagliptin 50mg. This dual-action formula targets different pathways involved in glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 500mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained-release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 500\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight-neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once or twice daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 500 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-500-133454",
"price": 289.0,
"discountamount": 86.7,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"GIP",
"diet",
"Order",
"EMAIL",
"water",
"glass",
"liver",
"GLP-1",
"peaks",
"meals",
"adults",
"amount",
"option",
"troughs",
"Fasting",
"exercise",
"Low Risk",
"patients",
"readings",
"response",
"Enhancing",
"same time",
"biguanide",
"Guidelines",
"one tablet",
"weight gain",
"Optimal Use",
"information",
"Adjustments",
"utilization",
"Vildagliptin",
"Metformin SR",
"sterispharma",
"Hypoglycemia",
"Introduction",
"best results",
"sterisonline",
"DPP-4 enzyme",
"muscle cells",
"CALL/WHATSAPP",
"glucose uptake",
"steady release",
"typical dosage",
"Key Components",
"treatment plan",
"Weight Neutral",
"Consistent Use",
"Administration",
"Incretin Levels",
"gradual release",
"low blood sugar",
"glycemic control",
"DPP-4) inhibitor",
"VILDIABATE M 500",
"glucagon release",
"Prolonged Effect",
"incretin hormones",
"insulin secretion",
"several mechanisms",
"different pathways",
"Regular monitoring",
"glucose regulation",
"dual-action formula",
"Insulin Sensitivity",
"healthcare provider",
"blood glucose levels",
"Intestinal Absorption",
"combination medication",
"gastrointestinal tract",
"dipeptidyl peptidase-4",
"type 2 diabetes mellitus",
"glucose-dependent manner",
"meal) blood sugar levels",
"Recommended Dosage Dosage",
"Additional Health Benefits",
"Hepatic Glucose Production",
"Extended Release Formulation",
"sustained-release formulation",
"prolonged therapeutic effects",
"immediate-release formulations",
"Postprandial Glucose Management",
"long-lasting blood sugar control",
"comprehensive blood sugar control",
"sustained-release (SR) formulation",
"common gastrointestinal side effects",
"Reduced Gastrointestinal Side Effects",
"Improving Postprandial Glucose Control",
"glucose-dependent insulinotropic peptide",
"Metformin Hydrochloride Sustained Release"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1499,
"imageuri": "https://productimages.withfloats.com/actual/667d4af8b567218985111efd.png",
"tileimageuri": "https://productimages.withfloats.com/tile/667d4af8b567218985111efd.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-07T07:08:22.623Z",
"updatedon": "2026-03-13T06:47:01.072Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//vildiabate-m-500-/1499",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "VILDIABATE M 500 ",
"category": "DIABETIC RANGE",
"tags": [
"vildagliptin metformin 50/1000",
"vildagliptin metformin 50/500 price",
"ildagliptin and metformin hydrochloride tablets si"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "6662af26db100e1fdc2dcc17",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "VILDIABATE M 1000 ",
"description": "VILDIABATE M 1000 \nMetformin (1000mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 1000\nVILDIABATE M 1000 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains Metformin Hydrochloride Sustained Release (SR) 1000mg and Vildagliptin 50mg. This dual-action formula targets different pathways involved in glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 1000mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 1000\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin, in particular, has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 1000 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-1000-133453",
"price": 319.0,
"discountamount": 95.7,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"GIP",
"diet",
"GLP-1",
"Order",
"EMAIL",
"water",
"glass",
"liver",
"peaks",
"meals",
"adults",
"amount",
"option",
"troughs",
"Fasting",
"exercise",
"Low Risk",
"patients",
"response",
"readings",
"same time",
"Enhancing",
"biguanide",
"one tablet",
"Guidelines",
"Optimal Use",
"information",
"utilization",
"weight gain",
"Adjustments",
"Introduction",
"Vildagliptin",
"Metformin SR",
"VILDIABATE M",
"sterispharma",
"best results",
"Hypoglycemia",
"sterisonline",
"DPP-4 enzyme",
"muscle cells",
"CALL/WHATSAPP",
"Weight Neutral",
"Consistent Use",
"Administration",
"treatment plan",
"steady release",
"typical dosage",
"Key Components",
"glucose uptake",
"low blood sugar",
"Incretin Levels",
"gradual release",
"SR) formulation",
"glucagon release",
"glycemic control",
"Prolonged Effect",
"DPP-4) inhibitor",
"insulin secretion",
"incretin hormones",
"several mechanisms",
"different pathways",
"glucose regulation",
"Regular monitoring",
"dual-action formula",
"healthcare provider",
"Insulin Sensitivity",
"blood glucose levels",
"effective management",
"Intestinal Absorption",
"gastrointestinal tract",
"combination medication",
"dipeptidyl peptidase-4",
"type 2 diabetes mellitus",
"glucose-dependent manner",
"meal) blood sugar levels",
"Recommended Dosage Dosage",
"Additional Health Benefits",
"Hepatic Glucose Production",
"Extended Release Formulation",
"sustained-release formulation",
"prolonged therapeutic effects",
"immediate-release formulations",
"Postprandial Glucose Management",
"long-lasting blood sugar control",
"comprehensive blood sugar control",
"common gastrointestinal side effects",
"Reduced Gastrointestinal Side Effects",
"Improving Postprandial Glucose Control",
"glucose-dependent insulinotropic peptide",
"Metformin Hydrochloride Sustained Release"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1496,
"imageuri": "https://productimages.withfloats.com/actual/6662af29d878d473a9fda03d.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6662af29d878d473a9fda03d.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-07T06:56:38.67Z",
"updatedon": "2026-03-13T06:46:17.898Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//vildiabate-m-1000-/1496",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "VILDIABATE M 1000 ",
"category": "DIABETIC RANGE",
"tags": [
"VILDIABATE M 1000",
"Metformin (1000mg)SR",
"Vildagliptin (50mg)",
"Vildagliptin 50mg side effects",
"Vildagliptin tablets 50 mg uses",
"Vildagliptin 50 mg price",
"Vildagliptin 50 mg and metformin 500 mg"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "66619067161afa2274ff4f3b",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Metformin SR 850mg",
"description": "SEIZMET SR 850 \nMetformin SR (850mg) \nIntroduction to SEIZMET SR 850\nSEIZMET SR 850 contains Metformin Hydrochloride 850mg in a sustained-release (SR) formulation. This medication is primarily used for the management of type 2 diabetes mellitus. Metformin belongs to a class of drugs known as biguanides, which help control blood sugar levels by improving the body's response to insulin. The sustained-release formulation ensures a prolonged effect throughout the day, providing steady glycemic control.\n\nWhat is Metformin?\nOverview of Metformin\nMetformin is an oral diabetes medication that helps lower blood sugar levels by improving insulin sensitivity and reducing glucose production in the liver. It also enhances glucose uptake and utilization in peripheral tissues, making it an effective treatment for type 2 diabetes.\n\nMechanism of Action\nInsulin Sensitization: Metformin works by decreasing hepatic glucose production and increasing insulin sensitivity in peripheral tissues, allowing cells to absorb glucose more effectively.\nGlucose Uptake: By enhancing insulin sensitivity, Metformin helps muscles and adipose tissues take up glucose from the bloodstream, lowering blood sugar levels.\nReduced Glucose Production: Metformin decreases the amount of glucose produced by the liver, contributing to overall glycemic control.\nBenefits of SEIZMET SR 850\nEffective Blood Sugar Management\nImproved Insulin Sensitivity: SEIZMET SR 850 helps improve the body's response to insulin, leading to better control of blood sugar levels.\nComprehensive Glycemic Control: By targeting both insulin sensitivity and hepatic glucose production, Metformin provides a unique mechanism of action that complements other diabetes medications, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: SEIZMET SR 850 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, SEIZMET SR 850 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Neutral or Loss: Unlike some other diabetes medications, Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nCardiovascular Benefits: Metformin has been shown to have beneficial effects on cardiovascular health, reducing the risk of heart disease and stroke in patients with type 2 diabetes.\nHow to Use SEIZMET SR 850\nDosage and Administration\nRecommended Dosage: The typical dosage of SEIZMET SR 850 is one tablet taken once daily with the evening meal. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take SEIZMET SR 850 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/seizmet-sr-850-133444",
"price": 43.0,
"discountamount": 13.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"day",
"body",
"Diet",
"cells",
"class",
"Order",
"EMAIL",
"drugs",
"water",
"meals",
"liver",
"amount",
"Action",
"stroke",
"option",
"Support",
"muscles",
"readings",
"Overview",
"biguanides",
"full glass",
"one tablet",
"neuropathy",
"overweight",
"Guidelines",
"bloodstream",
"utilization",
"information",
"retinopathy",
"Optimal Use",
"Adjustments",
"Metformin SR",
"Introduction",
"sterispharma",
"Reduced Risk",
"best results",
"evening meal",
"sterisonline",
"heart disease",
"CALL/WHATSAPP",
"SEIZMET SR 850",
"glucose uptake",
"Consistent Use",
"Administration",
"Weight Neutral",
"obese patients",
"typical dosage",
"treatment plan",
"unique mechanism",
"Exercise Adjunct",
"prolonged effect",
"excellent adjunct",
"Recommended Dosage",
"modest weight loss",
"peripheral tissues",
"beneficial effects",
"blood sugar control",
"individual response",
"Diabetes Management",
"effective treatment",
"healthcare provider",
"insulin sensitivity",
"cardiovascular health",
"Insulin Sensitization",
"cardiovascular disease",
"Metformin Hydrochloride",
"steady glycemic control",
"Cardiovascular Benefits",
"long-term complications",
"lifestyle modifications",
"type 2 diabetes mellitus",
"overall glycemic control",
"oral diabetes medication",
"stable blood sugar levels",
"Reduced Glucose Production",
"Additional Health Benefits",
"hepatic glucose production",
"other diabetes medications",
"gastrointestinal discomfort",
"sustained-release formulation",
"Comprehensive Glycemic Control",
"Effective Blood Sugar Management",
"sustained-release (SR) formulation",
"comprehensive blood sugar management"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1451,
"imageuri": "https://productimages.withfloats.com/actual/66619068c06ee12d88cfeb92.jpg",
"tileimageuri": "https://productimages.withfloats.com/tile/66619068c06ee12d88cfeb92.jpg",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-06T10:33:11.434Z",
"updatedon": "2026-03-13T06:30:27.801Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//metformin-sr-850mg/1451",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "SEIZMET SR 850 ",
"category": "DIABETIC RANGE",
"tags": [
"SEIZMET SR 850",
"Metformin SR (850mg)",
"Glycomet 850 SR in pregnancy",
"Glycomet SR 850 composition",
"Glycomet SR 850 side effects",
"Metformin 850 mg price",
"Glycomet 850 SR uses"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "665efdbd66170d1ff8cb13bf",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Dapaflozin 10 mg, Sitagliptin 100 mg & Metformin SR 500 mg",
"description": "GLIDAPA 3D 10/100/500 SR \nDapaflozin 10 mg, Sitagliptin 100 mg & Metformin SR 500 mg\nIntroduction\nGLIDAPA 3D 10/100/500 SR is a sophisticated, multi-mechanism oral medication designed for the management of Type 2 diabetes. It combines Dapagliflozin (10 mg), Sitagliptin (100 mg), and Metformin (500 mg, sustained release), offering a robust, integrated approach to controlling high blood glucose levels.\n\nMechanism of Action\n\nDapagliflozin (10 mg): As an SGLT2 inhibitor, Dapagliflozin promotes the excretion of glucose through urine by blocking its reabsorption in the kidneys. This helps to lower blood sugar levels and also has benefits for weight loss and cardiovascular health.\nSitagliptin (100 mg): A DPP-4 inhibitor, Sitagliptin works by enhancing the body's own ability to lower blood glucose levels in response to meals. It does this by increasing the levels of incretin hormones, which affect the pancreas to produce more insulin and less glucagon.\nMetformin SR (500 mg): Metformin works primarily by reducing glucose production in the liver, improving insulin sensitivity, and lowering glucose absorption in the gut. The sustained-release (SR) formulation ensures a steady release over time, minimizing gastrointestinal side effects and maintaining more consistent blood sugar control.\nBenefits\nGLIDAPA 3D 10/100/500 SR provides a comprehensive treatment solution by addressing several key pathways in glucose metabolism, thereby reducing the risk of both hyperglycemia and associated complications. The combination of these three active substances in a single formulation enhances convenience and potentially improves adherence to treatment protocols.\n\nDosage and Administration\n\nDosage: The recommended starting dose depends on the patient’s current treatment regimen and their specific health profile. Adjustments should be made based on effectiveness and tolerability, under the guidance of a healthcare professional.\nAdministration: This medication should be taken once daily in the morning, with or without food. The tablet should be swallowed whole to maintain the sustained release of Metformin.\nSide Effects\nPossible side effects of GLIDAPA 3D 10/100/500 SR include urinary tract and genital infections (due to Dapagliflozin), nausea or a sore throat (from Sitagliptin), and digestive issues such as diarrhea or abdominal pain (common with Metformin). Most side effects are manageable and tend to decrease over time.\n\nConclusion\nGLIDAPA 3D 10/100/500 SR is a versatile and effective option for those managing Type 2 diabetes, offering triple-action treatment in one convenient medication. It targets various aspects of diabetes management, improves glycemic control, and enhances overall quality of life. Patients are advised to maintain regular follow-ups with their healthcare provider to optimize treatment outcomes and manage any side effects.\nFor further information:\nEMAIL: info@sterispharma.com / contact@sterispharma.com \n Order Now\n",
"price": 539.0,
"discountamount": 162.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"gut",
"time",
"life",
"risk",
"food",
"body",
"urine",
"liver",
"EMAIL",
"Order",
"meals",
"500 mg",
"nausea",
"tablet",
"patient",
"ability",
"kidneys",
"morning",
"response",
"diarrhea",
"pancreas",
"guidance",
"benefits",
"adherence",
"versatile",
"excretion",
"Conclusion",
"sore throat",
"Sitagliptin",
"weight loss",
"Adjustments",
"combination",
"information",
"convenience",
"Introduction",
"sterispharma",
"Metformin SR",
"reabsorption",
"sterisonline",
"urinary tract",
"CALL/WHATSAPP",
"hyperglycemia",
"Dapagliflozin",
"less glucagon",
"effectiveness",
"starting dose",
"abdominal pain",
"steady release",
"overall quality",
"SGLT2 inhibitor",
"various aspects",
"Type 2 diabetes",
"DPP-4 inhibitor",
"Dapaflozin 10 mg",
"effective option",
"digestive issues",
"glycemic control",
"Most side effects",
"sustained release",
"incretin hormones",
"regular follow-ups",
"genital infections",
"blood sugar levels",
"glucose metabolism",
"glucose absorption",
"glucose production",
"treatment outcomes",
"single formulation",
"diabetes management",
"insulin sensitivity",
"healthcare provider",
"treatment protocols",
"several key pathways",
"Administration Dosage",
"Possible side effects",
"cardiovascular health",
"triple-action treatment",
"specific health profile",
"three active substances",
"healthcare professional",
"associated complications",
"GLIDAPA 3D 10/100/500 SR",
"current treatment regimen",
"one convenient medication",
"high blood glucose levels",
"robust, integrated approach",
"gastrointestinal side effects",
"consistent blood sugar control",
"comprehensive treatment solution",
"sustained-release (SR) formulation",
"sophisticated, multi-mechanism oral medication"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1300,
"imageuri": "https://productimages.withfloats.com/actual/665efdc0e874b19df8b5f4ce.png",
"tileimageuri": "https://productimages.withfloats.com/tile/665efdc0e874b19df8b5f4ce.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-04T11:42:53.803Z",
"updatedon": "2026-03-13T07:20:46.914Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//dapaflozin-10-mg-sitagliptin-100-mg-metformin-sr-500-mg/1300",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLIDAPA 3D 10/100/500 SR ",
"category": "DIABETIC RANGE",
"tags": [],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "665efc4cea22b014e8af0117",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Teneligliptin 20mg & Dapagliflozin Propanediol Monohydrate 5mg",
"description": "GLIDAPA TENE 5/20 \nTeneligliptin 20mg & Dapagliflozin Propanediol Monohydrate 5mg\nIntroduction\nGLIDAPA TENE 5/20 is an advanced combination medication tailored for the management of Type 2 diabetes. This oral formulation brings together Teneligliptin (20 mg) and Dapagliflozin Propanediol Monohydrate (5 mg), optimizing glucose control through dual mechanisms of action.\n\nHow It Works\n\nTeneligliptin (20 mg): As a DPP-4 inhibitor, Teneligliptin enhances the body’s natural insulin response after meals. It works by prolonging the activity of incretin hormones, which increase insulin release and decrease glucagon production, particularly post-prandially. This results in a reduction of blood glucose spikes.\nDapagliflozin Propanediol Monohydrate (5 mg): Functioning as an SGLT2 inhibitor, Dapagliflozin helps the kidneys eliminate glucose from the bloodstream through the urine. This not only lowers blood sugar levels but also assists in weight management and may have cardiovascular benefits.\nBenefits\nThe combination of Teneligliptin and Dapagliflozin in GLIDAPA TENE 5/20 offers a potent therapeutic approach by attacking diabetes on two fronts. This enhances glycemic control, reduces the risk of hypoglycemia compared to other therapies, and can contribute to weight loss — a beneficial side effect for many individuals with Type 2 diabetes.\n\nDosage and Administration\n\nDosage: Typically prescribed as one tablet per day, the dosage may need adjustments based on individual efficacy and tolerability.\nAdministration: GLIDAPA TENE 5/20 should be taken in the morning, with or without food. Consistency in the timing of dosage is crucial for maintaining steady drug levels and optimizing effectiveness.\nSide Effects\nCommon side effects include urinary tract infections and genital infections due to increased sugar in urine, and potential gastrointestinal issues like nausea. Dehydration is a risk factor due to the diuretic effect of Dapagliflozin, making it important for patients to maintain adequate hydration.\n\nConclusion\nGLIDAPA TENE 5/20 represents a significant advancement in the treatment of Type 2 diabetes, combining two effective drugs that provide complementary actions to improve blood sugar control. This combination can simplify the treatment regimen, enhance patient adherence, and lead to better overall management of diabetes. Patients should engage closely with their healthcare providers to tailor the treatment plan to their specific needs and monitor their health closely to optimize outcomes.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/glidapa-tene-5-20-134232",
"price": 225.0,
"discountamount": 67.5,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"mg",
"day",
"body",
"food",
"Order",
"meals",
"EMAIL",
"urine",
"timing",
"nausea",
"kidneys",
"morning",
"outcomes",
"activity",
"patients",
"reduction",
"one tablet",
"two fronts",
"Conclusion",
"weight loss",
"information",
"Dehydration",
"adjustments",
"risk factor",
"Consistency",
"bloodstream",
"sterispharma",
"hypoglycemia",
"Introduction",
"sterisonline",
"tolerability",
"glidapa-tene",
"GLIDAPA TENE",
"effectiveness",
"CALL/WHATSAPP",
"Teneligliptin",
"specific needs",
"treatment plan",
"other therapies",
"SGLT2 inhibitor",
"DPP-4 inhibitor",
"dual mechanisms",
"insulin release",
"Type 2 diabetes",
"glucose control",
"diuretic effect",
"glycemic control",
"oral formulation",
"many individuals",
"weight management",
"incretin hormones",
"treatment regimen",
"patient adherence",
"overall management",
"steady drug levels",
"genital infections",
"adequate hydration",
"blood sugar levels",
"blood sugar control",
"individual efficacy",
"Common side effects",
"two effective drugs",
"glucagon production",
"blood glucose spikes",
"healthcare providers",
"Administration Dosage",
"complementary actions",
"beneficial side effect",
"cardiovascular benefits",
"significant advancement",
"urinary tract infections",
"natural insulin response",
"potent therapeutic approach",
"advanced combination medication",
"potential gastrointestinal issues",
"Dapagliflozin Propanediol Monohydrate"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1299,
"imageuri": "https://productimages.withfloats.com/actual/665efc4dd93d0ca61a49878b.png",
"tileimageuri": "https://productimages.withfloats.com/tile/665efc4dd93d0ca61a49878b.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-04T11:36:44.342Z",
"updatedon": "2026-03-13T10:44:32.625Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//teneligliptin-20mg-dapagliflozin-propanediol-monohydrate-5mg/1299",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLIDAPA TENE 5/20 ",
"category": "DIABETIC RANGE",
"tags": [
"Teneligliptin 20mg & Dapagliflozin Propanediol Monohydrate 5mg",
"teneligliptin 20 mg dapagliflozin 5 mg tablets uses",
"teneligliptin dapagliflozin combination benefits for diabetes",
"teneligliptin dapagliflozin tablet dosage guide",
"teneligliptin dapagliflozin tablets how it works for blood sugar",
"teneligliptin dapagliflozin tablet side effects in diabetes patients",
"teneligliptin dapagliflozin tablets for uncontrolled diabetes"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "665ef7cfea22b014e8aefff9",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "GLICLAGLAZE MR 30 ",
"description": "GLICLAGLAZE MR 30 \ngliclazide sr (30 mg)\nIntroduction\nGLICLAGLAZE MR 30 is specifically formulated for individuals managing Type 2 diabetes. This medication utilizes a sustained release (SR) form of Gliclazide at a 30 mg dosage, focusing on providing a steady, controlled release of the drug to maintain optimal blood sugar levels throughout the day.\n\nHow It Works\n\nGliclazide SR (30 mg): Gliclazide is a sulfonylurea class drug that increases insulin secretion from the pancreas. Unlike standard formulations, the SR version releases the medication gradually, which helps to stabilize blood sugar levels and reduces the risk of severe fluctuations that can lead to hypoglycemia. This mechanism not only enhances the body’s natural insulin use but also supports overall vascular health, decreasing the risk of complications associated with diabetes, such as cardiovascular disease.\nBenefits\nGLICLAGLAZE MR 30 is an excellent choice for patients who require a mild enhancement in their insulin secretion with a lower risk of hypoglycemia. The SR formulation provides a more predictable pharmacokinetic profile, which is crucial for maintaining a stable glycemic control. This can significantly improve the quality of life for patients by reducing common side effects associated with blood sugar spikes and drops.\n\nDosage and Administration\n\nDosage: The dose of GLICLAGLAZE MR 30 should be adjusted based on the patient’s blood glucose response and previous treatment history. Regular monitoring of blood glucose and glycated hemoglobin (HbA1c) levels is recommended to ensure that the dosage is effective.\nAdministration: This medication should be taken with breakfast or the first main meal of the day. The tablet should be swallowed whole to maintain the integrity of the sustained release mechanism.\nSide Effects\nPossible side effects of GLICLAGLAZE MR 30 include gastrointestinal issues such as nausea and upset stomach. Due to its sulfonylurea component, there is a risk of hypoglycemia, although it is generally lower compared to other sulfonylureas due to the sustained release formulation.\n\nConclusion\nGLICLAGLAZE MR 30 is a practical and effective solution for managing Type 2 diabetes, especially suited for patients seeking a gentle modification in their diabetes treatment plan with sustained drug release. It simplifies diabetes management, potentially enhancing adherence and minimizing the risk of dosage-related complications. As with any medication, consultation with a healthcare provider is essential to tailor the treatment to individual needs and conditions.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-mr-30-133422",
"price": 83.0,
"discountamount": 24.9,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"day",
"dose",
"life",
"body",
"drops",
"EMAIL",
"Order",
"upset",
"tablet",
"nausea",
"stomach",
"quality",
"SR) form",
"patients",
"Benefits",
"pancreas",
"adherence",
"integrity",
"breakfast",
"practical",
"lower risk",
"SR version",
"medication",
"conditions",
"Conclusion",
"individuals",
"information",
"sterisonline",
"Introduction",
"30 mg dosage",
"consultation",
"sterispharma",
"hypoglycemia",
"CALL/WHATSAPP",
"Gliclazide SR",
"HbA1c) levels",
"SR formulation",
"GLICLAGLAZE MR",
"first main meal",
"Type 2 diabetes",
"mild enhancement",
"individual needs",
"excellent choice",
"insulin secretion",
"effective solution",
"Regular monitoring",
"blood sugar spikes",
"healthcare provider",
"diabetes management",
"gentle modification",
"other sulfonylureas",
"common side effects",
"glycated hemoglobin",
"severe fluctuations",
"natural insulin use",
"Possible side effects",
"standard formulations",
"Administration Dosage",
"sulfonylurea component",
"sustained drug release",
"blood glucose response",
"cardiovascular disease",
"diabetes treatment plan",
"stable glycemic control",
"gastrointestinal issues",
"overall vascular health",
"sulfonylurea class drug",
"steady, controlled release",
"optimal blood sugar levels",
"previous treatment history",
"sustained release mechanism",
"dosage-related complications",
"sustained release formulation",
"predictable pharmacokinetic profile"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1291,
"imageuri": "https://productimages.withfloats.com/actual/665ef7d253245b8b6b459895.png",
"tileimageuri": "https://productimages.withfloats.com/tile/665ef7d253245b8b6b459895.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-04T11:17:35.736Z",
"updatedon": "2024-06-04T11:17:35.736Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//gliclaglaze-mr-30-/1291",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLICLAGLAZE MR 30 ",
"category": "DIABETIC RANGE",
"tags": null,
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
}
],
"hasmoreitems": false,
"isapirequest": false,
"totalresults": 27,
"query": null,
"floatingpoint": null
}